These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 31454466)

  • 21. Optimization of hepatitis C virus screening strategies by birth cohort in Italy.
    Kondili LA; Gamkrelidze I; Blach S; Marcellusi A; Galli M; Petta S; Puoti M; Vella S; Razavi H; Craxi A; Mennini FS;
    Liver Int; 2020 Jul; 40(7):1545-1555. PubMed ID: 32078234
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-effectiveness and health-related outcomes of screening for hepatitis C in Korean population.
    Kim KA; Chung W; Choi HY; Ki M; Jang ES; Jeong SH
    Liver Int; 2019 Jan; 39(1):60-69. PubMed ID: 29998565
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Systematic review: economic evaluations of HCV screening in the direct-acting antivirals era.
    Cortesi PA; Barca R; Giudicatti G; Mossini S; Ciaccio A; Iannazzo S; Micale M; Cesana G; Mantovani LG
    Aliment Pharmacol Ther; 2019 May; 49(9):1126-1133. PubMed ID: 30843268
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tailored screening and dedicated funding for direct acting antiviral drugs: how to keep Italy on the road to hepatitis C virus elimination?
    Kondili LA; Blach S; Razavi H; Craxì A
    Ann Ist Super Sanita; 2020; 56(3):325-329. PubMed ID: 32959798
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hepatitis C Elimination in Rwanda: Progress, Feasibility, and Economic Evaluation.
    Zhong H; Aaron A; Hiebert L; Serumondo J; Zhuo Y; Adee M; Rwibasira GN; Ward JW; Chhatwal J
    Value Health; 2024 Jul; 27(7):918-925. PubMed ID: 38492923
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hepatitis C Elimination in Moldova Is Feasible and Cost-Saving: A Modeling Study.
    Aaron A; Zhong H; Hiebert L; Zhuo Y; Adee M; Paraschiv A; Stratulat S; Ward JW; Chhatwal J
    J Infect Dis; 2023 Sep; 228(Suppl 3):S189-S197. PubMed ID: 37703345
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Modelling the Impact and Cost-effectiveness of Extended Hepatitis C Virus Screening and Treatment with Direct-acting Antivirals in a Swiss Custodial Setting.
    Girardin F; Hearmon N; Castro E; Negro F; Eddowes L; Gétaz L; Wolff H
    Clin Infect Dis; 2019 Nov; 69(11):1980-1986. PubMed ID: 30715266
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Economic model of a birth cohort screening program for hepatitis C virus.
    McGarry LJ; Pawar VS; Panchmatia HR; Rubin JL; Davis GL; Younossi ZM; Capretta JC; O'Grady MJ; Weinstein MC
    Hepatology; 2012 May; 55(5):1344-55. PubMed ID: 22135116
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost effectiveness of direct-acting antiviral therapy for treatment-naive patients with chronic HCV genotype 1 infection in the veterans health administration.
    Chan K; Lai MN; Groessl EJ; Hanchate AD; Wong JB; Clark JA; Asch SM; Gifford AL; Ho SB
    Clin Gastroenterol Hepatol; 2013 Nov; 11(11):1503-10. PubMed ID: 23707354
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Direct-Acting Antiviral Agents for Patients With Hepatitis C Virus Genotype 1 Infection Are Cost-Saving.
    Chhatwal J; He T; Hur C; Lopez-Olivo MA
    Clin Gastroenterol Hepatol; 2017 Jun; 15(6):827-837.e8. PubMed ID: 27650326
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Systematic review: cost-effectiveness of direct-acting antivirals for treatment of hepatitis C genotypes 2-6.
    He T; Lopez-Olivo MA; Hur C; Chhatwal J
    Aliment Pharmacol Ther; 2017 Oct; 46(8):711-721. PubMed ID: 28836278
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Estimating the Cost-Effectiveness of One-Time Screening and Treatment for Hepatitis C in Korea.
    Kim DY; Han KH; Jun B; Kim TH; Park S; Ward T; Webster S; McEwan P
    PLoS One; 2017; 12(1):e0167770. PubMed ID: 28060834
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Liver disease burden and required treatment expenditures for hepatitis C virus (HCV) infection in Thailand: Implications for HCV elimination in the new therapeutic era, a population-based study.
    Wasitthankasem R; Vichaiwattana P; Siripon N; Posuwan N; Auphimai C; Klinfueng S; Thanetkongtong N; Vuthitanachot V; Saiyatha S; Thongmai C; Sochoo S; Pongsuwan N; Poovorawan K; Tangkijvanich P; Poovorawan Y
    PLoS One; 2018; 13(4):e0196301. PubMed ID: 29689073
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hepatitis C disease burden and strategies for elimination by 2030 in Brazil. A mathematical modeling approach.
    Benzaken AS; Girade R; Catapan E; Pereira GFM; Almeida EC; Vivaldini S; Fernandes N; Razavi H; Schmelzer J; Ferraz ML; Ferreira PRA; Pessoa MG; Martinelli A; Souto FJD; Walsh N; Mendes-Correa MC
    Braz J Infect Dis; 2019; 23(3):182-190. PubMed ID: 31145876
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost-effectiveness and budgetary impact of HCV treatment with direct-acting antivirals in India including the risk of reinfection.
    Chaillon A; Mehta SR; Hoenigl M; Solomon SS; Vickerman P; Hickman M; Skaathun B; Martin NK
    PLoS One; 2019; 14(6):e0217964. PubMed ID: 31170246
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The cost-effectiveness of testing for hepatitis C in former injecting drug users.
    Castelnuovo E; Thompson-Coon J; Pitt M; Cramp M; Siebert U; Price A; Stein K
    Health Technol Assess; 2006 Sep; 10(32):iii-iv, ix-xii, 1-93. PubMed ID: 16948891
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Elimination of Hepatitis C Virus in Australia: Laying the Foundation.
    Dore GJ; Hajarizadeh B
    Infect Dis Clin North Am; 2018 Jun; 32(2):269-279. PubMed ID: 29778255
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combined treatment and prevention strategies for hepatitis C virus elimination in the prisons in New South Wales: a modelling study.
    Bretaña NA; Gray RR; Cunningham EB; Betz-Stablein B; Ribeiro R; Graw F; Luciani F; Lloyd AR
    Addiction; 2020 May; 115(5):901-913. PubMed ID: 31633853
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Strategies for Removal of Barriers to Hepatitis C Elimination in Sub-Saharan Africa.
    Umutesi J; Yu ML; Lesi O; Ward JW; Serumondo J
    J Infect Dis; 2023 Sep; 228(Suppl 3):S221-S225. PubMed ID: 37703337
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hepatitis C elimination in Myanmar: Modelling the impact, cost, cost-effectiveness and economic benefits.
    Scott N; Win TM; Tidhar T; Htay H; Draper B; Aung PTZ; Xiao Y; Bowring A; Kuschel C; Shilton S; Kyi KP; Naing W; Aung KS; Hellard M
    Lancet Reg Health West Pac; 2021 May; 10():100129. PubMed ID: 34327345
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.